EA201491185A1 - Полимеры альфа-аминоамидинов и их применение - Google Patents

Полимеры альфа-аминоамидинов и их применение

Info

Publication number
EA201491185A1
EA201491185A1 EA201491185A EA201491185A EA201491185A1 EA 201491185 A1 EA201491185 A1 EA 201491185A1 EA 201491185 A EA201491185 A EA 201491185A EA 201491185 A EA201491185 A EA 201491185A EA 201491185 A1 EA201491185 A1 EA 201491185A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polymers
aminoamidine
aminoamidine polymers
aminoamidines
polynucleotides
Prior art date
Application number
EA201491185A
Other languages
English (en)
Inventor
Артуро Хосе Вегас
Кэтрин Энн Уайтхэд
Дэниэл Гриффит Андерсон
Роберт С. Лангер
Джозеф Р. Доркин
Original Assignee
Массачусетс Инститьют Оф Текнолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Массачусетс Инститьют Оф Текнолоджи filed Critical Массачусетс Инститьют Оф Текнолоджи
Publication of EA201491185A1 publication Critical patent/EA201491185A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
    • C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
    • C08G12/04—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with acyclic or carbocyclic compounds
    • C08G12/06—Amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
    • C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
    • C08G12/26—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds
    • C08G12/34—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds and acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyamides (AREA)

Abstract

Описываются полимеры α-аминоамидинов и способы получения полимеров α-аминоамидинов реакцией одного или более аминов с одним или более изоцианидов и одним или более альдегидов. Также предусматриваются способы получения полимеров α-аминоамидинов из коммерчески доступных исходных материалов, которые являются рацемическими или стереохимически чистыми. Полимеры α-аминоамидинов или их солевые формы предпочтительно являются биоразлагаемыми или биосовместимыми и могут применяться в различных системах доставки лекарственных средств и для других целей, например, таких как покрытия, добавки, эксципиенты, пластики и материалы и т.д. Поскольку в этих полимерах α-аминоамидинов имеется аминогруппа, они особенно применимы для доставки полинуклеотидов. Можно получать комплексы, мицеллы, липосомы или частицы, содержащие полимеры α-аминоамидинов по изобретению и полинуклеотиды. Полимеры α-аминоамидинов по изобретению можно также применять для получения микрочастиц для доставки лекарственных средств. В частности, учитывая их способность буферизовать среду, их можно применять для доставки неустойчивых агентов.
EA201491185A 2011-12-16 2012-12-15 Полимеры альфа-аминоамидинов и их применение EA201491185A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576899P 2011-12-16 2011-12-16
PCT/US2012/069961 WO2013090861A1 (en) 2011-12-16 2012-12-15 Alpha-aminoamidine polymers and uses thereof

Publications (1)

Publication Number Publication Date
EA201491185A1 true EA201491185A1 (ru) 2015-05-29

Family

ID=47501483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491185A EA201491185A1 (ru) 2011-12-16 2012-12-15 Полимеры альфа-аминоамидинов и их применение

Country Status (9)

Country Link
US (1) US9872911B2 (ru)
EP (1) EP2791210A1 (ru)
CN (1) CN104245794A (ru)
AU (1) AU2012351967A1 (ru)
BR (1) BR112014014599A2 (ru)
CA (1) CA2859205A1 (ru)
EA (1) EA201491185A1 (ru)
IN (1) IN2014DN05912A (ru)
WO (1) WO2013090861A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc MULTIMEPEPTID CONJUGATES AND ITS USES
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2622064B1 (en) 2010-10-01 2019-05-29 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3155116A4 (en) 2014-06-10 2017-12-27 Massachusetts Institute Of Technology Method for gene editing
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
BR112021003897A2 (pt) 2018-08-30 2021-05-25 Tenaya Therapeutics, Inc. reprogramação de células cardíacas com miocarina e asci1
US20220031631A1 (en) * 2018-09-19 2022-02-03 Modernatx, Inc. High-purity peg lipids and uses thereof
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
CN112876677B (zh) * 2020-12-29 2022-05-06 浙江大学杭州国际科创中心 一种多巴胺功能化聚(β-氨基酯)及其制备方法和应用
CN114315889B (zh) * 2021-12-20 2024-03-22 广东万木新材料科技有限公司 一种双官能有机二硅醚类化合物及其合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155174A (en) 1989-05-08 1992-10-13 American Cyanamid Company Surface-modified polyacrylonitrile fibrous substrates
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
SE519326C2 (sv) 1999-11-22 2003-02-11 Astrazeneca Ab Funktionaliserade polymera reagens innefattande en syralabil isonitrildel samt förfarande för dess framställning
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
US20030211139A1 (en) * 2002-05-07 2003-11-13 Thierry Legon Dispersions of lipid particles for use as therapeutic and cosmetic agents and intracellular delivery vehicles
TW200640493A (en) 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
CN101346468B (zh) 2005-06-15 2016-03-30 麻省理工学院 含胺脂质和其用途
WO2007143659A2 (en) 2006-06-05 2007-12-13 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
US8071082B2 (en) 2006-07-21 2011-12-06 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20090191244A1 (en) 2007-09-27 2009-07-30 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用

Also Published As

Publication number Publication date
BR112014014599A2 (pt) 2017-06-13
WO2013090861A8 (en) 2013-08-22
US9872911B2 (en) 2018-01-23
IN2014DN05912A (ru) 2015-06-05
AU2012351967A1 (en) 2014-07-17
CA2859205A1 (en) 2013-06-20
WO2013090861A1 (en) 2013-06-20
US20140322309A1 (en) 2014-10-30
CN104245794A (zh) 2014-12-24
EP2791210A1 (en) 2014-10-22

Similar Documents

Publication Publication Date Title
EA201491185A1 (ru) Полимеры альфа-аминоамидинов и их применение
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
MX2023000745A (es) Composiciones para usarse en el suministro de agentes biomacromoleculares.
EA201990169A1 (ru) Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201690930A1 (ru) Композиции и способы модуляции фарнезоидных х-рецепторов
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EP3329919A8 (en) Acc inhibitors and uses thereof
MX2021001144A (es) Lipidoides de aminoalcohol y usos de los mismos.
CY1118858T1 (el) Νεα παραγωγα πυριμιδινης, παρασκευη αυτων και φαρμακευτικη χρηση αυτων ως αναστολεων φωσφορυλιωσης ακτ(ρκβ)
EA201890771A1 (ru) Соли и твердые формы монобактамного антибиотика
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX352245B (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
RU2015140720A (ru) Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой
EA201391481A1 (ru) Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования
EA201490756A1 (ru) Разагилина цитрамид
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
EA201490032A1 (ru) Лиофилизированные препараты fgf-18
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
EA201401200A1 (ru) Новая композиция альфентанила для лечения острой боли
MX2016010871A (es) Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина